
    
      Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing
      regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of
      chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT
      as a predictive value for progression free survival and overall survival is evaluated
    
  